Capmatinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Capmatinib. Educational only — not medical advice.
Labeled uses
TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Source: FDA labeling via NIH DailyMed (set 455892c3…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.